Associated tags: TSX, Pharmaceutical industry, Conference
Locations: CHICAGO, ILLINOIS, UNITED STATES, CANADA, ONTARIO, NYC, EUROPE, FINLAND, WORLD TRADE CENTER, NEW YORK, SAN FRANCISCO, MISSISSAUGA, ON, CA, TESLA
Sale,
FDA,
CMS,
International,
Urology,
PIN,
Food,
Travel,
Software,
TSX,
Insurance,
S&D,
Research,
Category 1,
Level 1,
Consultant,
Intelligence,
Prostate cancer,
Webcast,
Prostate,
International Financial Reporting Standards,
OPPS,
GG5,
Patient,
GG1,
Medicare,
MRI,
G&A,
Marketing,
Veterans' affairs,
Telephone,
Food and Drug Administration,
Growth,
BPH TORONTO, May 09, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the first quarter ended March 31, 2024 and provided full-year 2024 revenue guidance.
Key Points:
- TORONTO, May 09, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the first quarter ended March 31, 2024 and provided full-year 2024 revenue guidance.
- Earlier this week, Profound announced that 25 TULSA-related scientific research presentations have already been delivered at major medical meetings around the world thus far in 2024.
- First quarter 2024 revenue increased approximately 3% from $1.86 million in the same three-month period a year ago.
- First quarter 2024 S&D expenses increased by 15% to approximately $2.4 million, compared with $2.1 million in the first quarter of 2023.
Congress,
Society,
Interventional radiology,
Mayo Clinic,
Urology,
Safety,
American Urological Association,
Poster,
American Roentgen Ray Society,
TSX,
Prostate cancer,
Prostate,
Salvage therapy,
Abdominal Radiology,
Patient,
ARRS,
AUA,
ECR,
Clinical trial,
SIR,
Annual general meeting,
JUA,
BPH,
Turku University Hospital,
EAU TORONTO, May 06, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, is pleased to announce that a total of 25 paper, poster and podium presentations highlighting the Transurethral Ultrasound Ablation (“TULSA”) procedure’s ability to effectively, safely and efficiently treat an unrivaled variety of prostate cancer and/or benign prostatic hyperplasia (“BPH”) patients have been made at major medical meetings already in 2024.
Key Points:
- “The TACT 5-year clinical trial data, along with multiple real-world reports on the safety, efficacy and durability of TULSA from U.S. commercial centers, such as Mayo Clinic in Florida, Busch Center in Georgia, and UT Southwestern Medical Center in Texas, as well as international user sites, like Sapporo Hokuyu Hospital in Japan, ALTA Klinik in Germany, and Turku University Hospital in Finland, add to the growing body of evidence supporting the potential of TULSA as a mainstream treatment for prostate disease,” said Arun Menawat, Profound’s CEO and Chairman.
- “The various presentations made at AUA and other major medical conferences have highlighted TULSA’s clinical use across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and BPH; to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer,” added Dr. Menawat.
- “Importantly, real-world data from top institutions is also consistently demonstrating similar outcomes to the TACT FDA regulatory study.
- We would like to take this opportunity to thank the many esteemed researchers and clinicians who have contributed to the growing awareness of TULSA among urologists, both at home and abroad, and look forward to continuing to build on that positive momentum as the year progresses.”
TORONTO, April 22, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its first quarter 2024 financial results after market close on Thursday, May 9, 2024.
Key Points:
- TORONTO, April 22, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its first quarter 2024 financial results after market close on Thursday, May 9, 2024.
- Profound management will host a conference call at 4:30 p.m.
- ET to review the financial results and discuss business developments in the period.
- First Quarter 2024 Results Conference Call Details:
TORONTO, April 09, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company’s business at the 2024 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 16, 2024 at 9:30 a.m. Eastern Time at the Metro Toronto Convention Centre.
Key Points:
- TORONTO, April 09, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company’s business at the 2024 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 16, 2024 at 9:30 a.m. Eastern Time at the Metro Toronto Convention Centre.
- The presentation will be broadcast live and archived on the Company's website at www.profoundmedical.com under "Webcasts" in the Investors section.
International,
Doctor of Philosophy,
PIN,
Prostate cancer,
Research,
Intelligence,
Telephone,
Marketing,
Webcast,
TSX,
Food,
GG5,
Sale,
Annual report,
Travel,
BPH,
S&D,
Consultant,
Prostate,
Level 1,
Food and Drug Administration,
Patient,
News,
Clinical trial,
Insurance,
G&A,
Siemens Healthineers,
International Financial Reporting Standards,
MRI,
Software,
GG1,
Category 1,
Cryptocurrency TORONTO, March 07, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the fourth quarter and full year ended December 31, 2023.
Key Points:
- TORONTO, March 07, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the fourth quarter and full year ended December 31, 2023.
- Fourth quarter 2023 revenue increased 60% from approximately $1.3 million in the same three-month period a year ago.
- G&A expenses for the 2023 fourth quarter increased by 41% to approximately $3.0 million, compared with approximately $2.1 million in the same period in 2022.
- Fourth quarter 2023 S&D expenses increased by 74% to approximately $2.9 million, compared with $1.7 million in the fourth quarter of 2022.
TORONTO, March 04, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference on Wednesday, March 13, 2024 at 11:15 a.m. Eastern Time at the Loews Miami Beach Hotel.
Key Points:
- TORONTO, March 04, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference on Wednesday, March 13, 2024 at 11:15 a.m. Eastern Time at the Loews Miami Beach Hotel.
- The fireside chat will be broadcast live and archived on the Company's website at www.profoundmedical.com under "Webcasts" in the Investors section.
Retrieved on:
Tuesday, February 27, 2024
Interventional oncology,
University College London,
Division,
FRCS,
Magnetic resonance,
Prostate cancer,
MD,
Temperature,
UCL,
TSX,
Surgeon,
BPH,
Prostate,
Patient,
Helium,
Diagnosis,
Deep learning,
Claustrophobia,
Workflow,
Siemens Healthineers,
MRI,
Cancer,
Partnership,
Medical imaging TULSA is a “one-and-done” procedure, performed in a single session that takes a few hours, and no hospital stay is required.
Key Points:
- TULSA is a “one-and-done” procedure, performed in a single session that takes a few hours, and no hospital stay is required.
- At less than 7,700 Lbs and 80 inches high, MAGNETOM Free.Max is the most lightweight, compact whole-body scanner ever offered by Siemens Healthineers.
- I commend the teams at Siemens Healthineers and Profound as they work to achieve the convergence of their respective diagnostic and interventional MR technologies.
- We look forward to collaborating with Profound to help expand access to TULSA as well.
Retrieved on:
Thursday, February 15, 2024
TORONTO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its fourth quarter and full year 2023 financial results after market close on Thursday, March 7, 2024.
Key Points:
- TORONTO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its fourth quarter and full year 2023 financial results after market close on Thursday, March 7, 2024.
- Profound management will host a conference call at 4:30 p.m.
- ET to review the financial results and discuss business developments in the period.
- Fourth Quarter and Full Year 2023 Results Conference Call Details:
Retrieved on:
Tuesday, January 16, 2024
TORONTO, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) ("Profound" or the "Company") is pleased to announce that the Company has entered into subscription agreements, dated as of January 16, 2024, with certain existing Canadian institutional investors, in connection with a non-brokered private placement (the "Private Placement") for aggregate gross proceeds of approximately US$2,937,502.
Key Points:
- TORONTO, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) ("Profound" or the "Company") is pleased to announce that the Company has entered into subscription agreements, dated as of January 16, 2024, with certain existing Canadian institutional investors, in connection with a non-brokered private placement (the "Private Placement") for aggregate gross proceeds of approximately US$2,937,502.
- In connection with the closing of the Private Placement, the Company is expected to issue an aggregate of 391,667 common shares in the capital of the Company ("Common Shares") at a price of US$7.50 per Common Share.
- All of the Common Shares issued in connection with the Private Placement will be subject to a four-month and one day statutory hold period.
- The closing of the Private Placement is expected to occur on or about January 17, 2024, subject to customary closing conditions.
Retrieved on:
Wednesday, January 3, 2024
Category 1,
Conference,
Cleveland Clinic,
Hospital,
Sale,
Johns Hopkins Hospital,
Cone Health Women's Hospital,
Prostate cancer,
Level 1,
Monroe Dunaway Anderson,
Investment,
TSX,
News,
Prostate,
Pharmaceutical industry Profound anticipates total revenues for the fourth quarter of 2023 to be in the approximate range of $1.9 million to $2.0 million, with the full amount coming from recurring revenue, which consists of the sale of TULSA-PRO® consumables, lease of medical devices, procedures and services associated with extended warranties.
Key Points:
- Profound anticipates total revenues for the fourth quarter of 2023 to be in the approximate range of $1.9 million to $2.0 million, with the full amount coming from recurring revenue, which consists of the sale of TULSA-PRO® consumables, lease of medical devices, procedures and services associated with extended warranties.
- This represents recurring revenue growth of between 51% and 59% year-over-year, and between 10% and 16% sequentially over the 2023 third quarter.
- For the full year 2023, Profound anticipates total revenues to be in the approximate range of $7.1 million to $7.2 million.
- These figures are preliminary and unaudited, and actual revenues may differ.
